Invenio Imaging Strengthens Leadership with New Board Members
Invenio Imaging, a cutting-edge company specializing in fresh tissue imaging and artificial intelligence, has made significant strides by appointing Adrian Whitford as an Independent Board Director. Alongside Whitford, the company welcomes Biao He from Oak BioCapital and John Seamans from Michigan Biomedical Venture Fund to its Board of Directors, reinforcing the leadership team as Invenio enhances its commercialization strategy.
Adrian Whitford: A Valuable Addition
Adrian Whitford brings a wealth of experience in global commercialization and marketing, particularly within the fields of oncology and digital health. His previous role as Worldwide President at Johnson & Johnson MedTech saw him contribute significantly to the commercialization efforts for robotic bronchoscopy, demonstrating his expertise in transforming innovative concepts into market-ready solutions. Currently the President of Biobot Surgical, Whitford focuses on advancing robotic-assisted methodologies for diagnosing and treating prostate cancer, while his past initiatives have centered on improving patient outcomes in both respiratory and immunology.
Insights from Leadership
Jay Trautman, PhD, President and CEO of Invenio Imaging, expressed enthusiasm about the new appointments. He highlighted Whitford’s remarkable ability to convey the value of clinically significant innovations, which accelerates their adoption in the medical community. Trautman underscored the importance of Whitford’s extensive experience in lung cancer and digital health as positive assets that will help broaden access to Invenio's imaging platform.
Commentary from Adrian Whitford
Expressing his enthusiasm for joining Invenio's board, Adrian stated, "I'm excited to join Invenio's board and support the team as they bring timely, actionable information into procedure-driven cancer care." He emphasized the innovative nature of Invenio's platform, mentioning it integrates rapid fresh tissue imaging with artificial intelligence analysis. Whitford looks forward to playing a role in shaping the company's market entry and commercialization strategies.
Technological Innovations and Regulatory Milestones
Invenio Imaging has also achieved a major milestone with the FDA granting Breakthrough Device Designation for its NIO Lung Cancer Reveal, an investigational AI image-analysis module. This module is designed to assist medical professionals in evaluating imaging from fresh bronchoscopic lung forceps biopsy specimens using the NIO Laser Imaging System. It is important to note that this investigational module is not yet cleared for clinical use in the United States, representing a significant step in the development of advanced image analysis solutions.
Future Directions
With its newly expanded Board, Invenio Imaging continues to prioritize the commercialization of its innovative technologies while enhancing access to its platform. The company's focus remains on streamlining clinical workflows to improve patient care outcomes significantly. As Invenio navigates the complexities of the medical device landscape, these strategic appointments aim to further solidify its position in the industry.
About Invenio Imaging
Invenio Imaging, a private medical device firm based in Santa Clara, California, is committed to enhancing cancer care through the integration of intraoperative fresh tissue imaging and artificial intelligence. The NIO Laser Imaging System, which is both FDA-registered and CE-marked, has successfully been utilized in over 12,500 procedures across various medical areas, including neurosurgery, bronchoscopy, urology, and endoscopy. Additionally, the company's first AI product, NIO Glioma Reveal, has received CE mark approval and is available for clinical applications in Europe.
Frequently Asked Questions
Who is Adrian Whitford?
Adrian Whitford is the new Independent Board Director at Invenio Imaging, bringing extensive experience in commercialization in oncology and digital health.
What is the role of Biao He at Invenio Imaging?
Biao He from Oak BioCapital has joined the Board of Directors, contributing investment expertise to Invenio Imaging's initiatives.
What is the NIO Lung Cancer Reveal?
The NIO Lung Cancer Reveal is an investigational AI image-analysis module designed to assist physicians with bronchoscopic lung biopsies.
How has Invenio Imaging's technology impacted patient care?
Invenio Imaging's solutions aim to improve clinical workflows and enhance patient outcomes through advanced imaging techniques.
What does the future hold for Invenio Imaging?
With its expanded Board and innovative technologies, Invenio Imaging is focused on commercialization and improving access to cancer care solutions.
